Australia markets open in 5 hours 14 minutes

Biocartis Group NV (BCART.BR)

Brussels - Brussels Delayed price. Currency in EUR
Add to watchlist
0.5830-0.0220 (-3.64%)
At close: 05:35PM CET
Full screen
Previous close0.6050
Open0.6090
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.5810 - 0.6090
52-week range0.5810 - 3.8450
Volume257,671
Avg. volume184,157
Market cap53.672M
Beta (5Y monthly)1.43
PE ratio (TTM)N/A
EPS (TTM)-1.2420
Earnings date22 Feb 2023 - 27 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.29
  • GlobeNewswire

    Press release Biocartis Group NV: Mandatory Conversion Bondholder Notification

    PRESS RELEASE: REGULATED INFORMATION5 December 2022, 17:40 CET Mandatory Conversion Bondholder Notification Capitalised terms not otherwise defined in this notice shall have the meaning given to them in the Terms and Conditions of the Bonds. Mechelen, Belgium, 5 December 2022 – This announcement constitutes a notice (the “Mandatory Conversion Bondholder Notification”) in accordance with, respectively, Condition 5(m)(v) of the terms and conditions of the 4.00% convertible bonds due 2024/2027 (the

  • GlobeNewswire

    Press release Biocartis Group NV: Disclosure of a transparency notification

    PRESS RELEASE: REGULATED INFORMATION 2 December 2022, 17:45 CET Disclosure of a transparency notification Mechelen, Belgium, 2 December 2022 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down miscellaneo

  • GlobeNewswire

    Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

    PRESS RELEASE: REGULATED INFORMATION 2 December 2022, 17:40 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 2 December 2022 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that following the successful completion of the capital increase through the offering of new shares (with extra-legal preferential rights for existing shareholders) that was announced on 16 November 2022, its share c